fda approves first oral glp-1 obesity drug august 1 2025 Foundayo, an alternative to Wegovy and Ozempic FDA Approves Oral Semaglutide as
Description
Inflammation is increasingly recognized as a key factor in the pathogenesis of PD (67)
[DOI] [PubMed] [Google Scholar] 35.Goke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, et al
"Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes"
10.1161/CIRCULATIONAHA.106.675355 26 GersteinH
The observed protective effects are mediated through multiple molecular mechanisms, including enhanced metabolic regulation, direct anti-proliferative actions, and augmented immune surveillance [16, 17]
